Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2021-09-28 00:00:00 ET · period of report 2021-09-27 · accession 0001562180-21-006136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-28 | 2021-09-27 | SNDX | Metzger Michael A | Pres, COO, Dir | S - Sale+OE | $19.51 | -24.4K | 17.7K | -58% | -$476.8K |
| D | 2021-09-28 | 2021-09-27 | SNDX | Metzger Michael A | Pres, COO, Dir | M - OptEx | $7.20 | +24.4K | 42.1K | +138% | +$175.9K |
| D | 2021-09-28 | 2021-09-27 | SNDX | Metzger Michael A | Pres, COO, Dir | M - OptEx | $0.00 | -24.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-27 | S | D | 24,437 | $19.51 | 17,659 | D | — | — | (F2) The sales price ranged from $19.02 to $19.96 |
| 2 | Common | Common Stock | 2021-09-27 | M | A | 24,437 | $7.20 | 42,096 | D | — | — | |
| 3 | Derivative | Stock Options (Right to buy) | 2021-09-27 | M | D | 24,437 | $0.00 | 0 | D | $7.20 · — to 2025-06-01 | 24,437 Common Stock | (F3) This option is fully vested. |